This is in line with a report that demonstrated that low-dose aldesleukin preferentially expanded Helios+ Tregs in patients with T1D (72), providing a rationale for the use of low-dose aldesleukin to reinvigorate exhausted Helioslo Tregs in patients with T1D (73). Here, IKZF2 is linked to type 1 diabetes mellitus.